The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A biomarker study of atezolizumab (atezo) + bevacizumab (bev) + carboplatin (carbo) + paclitaxel (pac) (ABCP) for patients with NSCLC harboring EGFR mutations (EGFRm) after failure of TKI therapy: NEJ043.
 
Satoshi Watanabe
Consulting or Advisory Role - Novartis
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD; Novartis; Taiho Pharmaceutical; Thermo Fisher Scientific
 
Jun Shiihara
No Relationships to Disclose
 
Ichiro Nakachi
Honoraria - AstraZeneca; Chugai Pharma; Fisher Scientific; Takeda
 
Hisashi Tanaka
No Relationships to Disclose
 
Mika Nakao
No Relationships to Disclose
 
Koichi Minato
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - Parexel/CALYX (Inst); Taiho Pharmaceutical (Inst)
 
Masahiro Seike
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi-Sankyo Company; Kyowa Hakko Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Taiho Pharmaceutical
 
Shinichi Sasaki
Consulting or Advisory Role - Daiichi Sankyo Company, Ltd.
Research Funding - Shionogi (Inst)
 
Akira Kisohara
No Relationships to Disclose
 
Susumu Takeuchi
No Relationships to Disclose
 
Ryoichi Honda
No Relationships to Disclose
 
Kei Takamura
No Relationships to Disclose
 
Yiwei Ling
No Relationships to Disclose
 
Shujiro Okuda
No Relationships to Disclose
 
Hiroshi Kagamu
Honoraria - AstraZeneca/Daiichi Sankyo; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical
Consulting or Advisory Role - ImmuniT Research Inc.
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for predicting response to cancer therapy
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihon-Shinyaku; Nihonkayaku; Novartis; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku; Sysmex
 
Toshiaki Kikuchi
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Eisai; GlaxoSmithKline; Insmed; Kyorin; Kyowa Kirin; Lilly O.; Meiji Seika Kaisha; Merck; MSD; Nipro Corporation; Novartis; Ono Pharmaceutical; Sanofi; Shionogi; Sumitomo Dainippon Pharma; Taiho Pharmaceutical; TERUMO; Viatris
Consulting or Advisory Role - AN2 Therapeutics; Janssen
Research Funding - Asahi Kasei; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Kyorin; Nippon Kayaku; Nobelpharma; Shionogi; Taiho Pharmaceutical; TEIJIN PHARMA
 
Kunihiko Kobayashi
Speakers' Bureau - AstraZeneca; Takeda